Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

Completed

Phase 4 Results

Summary of Purpose

The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, Myocardial infarction (MI), stroke or hospitalization for Congestive Heart Failure (CHF) compared with ramipril 10mg...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 13 May 2014.

1 Nov 2001 9 Sep 2005 1 Jun 2008 Unavailable 1 May 2014 15 Jun 2009
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Purpose: Prevention
  • Intervention: Parallel Assignment

Contacts

  • Ingrid Copland ONTARGET/TRANSCEND Research Coordinator Population Health Research Institute Hamilton General Hospital McMaster Clinic, Rm 355 237 Barton St. East Hamilton, ON L8L 2X2, Canada Tel: 905-527-4322 ext. 44520 Email: Ingrid@ccc.mcmaster.ca

    yusufs@mcmaster.ca